Steady price for GSK stock as GBX 2,016.75 resistance holds

Traders Union
All News
Financial News
GSK up 0.41% today at GBX1,850.50

Highlights

GSK initiated the final phase of its £2 billion share buyback, with up to £180 million in ordinary shares targeted for repurchase.
The company expanded its global footprint by partnering with Sino Biopharmaceutical to prepare the hepatitis B drug bepirovirsen for launch in China.
Technically, shares trade below short- and medium-term moving averages with persistently negative momentum, forecasting a sideways-to-bearish range of GBX 1,849.00 to GBX 1,875.00 for the coming week.

Share buyback and China drug partnership bolster capital return and reach

GSK has launched the final stage of its £2 billion share buyback programme, with plans to repurchase up to £180 million in ordinary shares. The buyback, executed under a non-discretionary agreement with Citigroup, directly decreases the share float and delivers capital to shareholders, supporting per-share financial metrics. To date, more than 114 million shares have already been repurchased for £1.82 billion, highlighting tangible capital return progress. In parallel, GSK finalized a strategic partnership with Sino Biopharmaceutical’s Chia Tai Tianqing to advance launch preparations for its hepatitis B drug bepirovirsen in China, broadening its international commercial reach.

Persistent oversold signals as price remains below key resistance

Price action remains stuck between key technical reference points: GBX 1,850.50 sits below the SMA-20 at GBX 2,027.80 and SMA-50 at GBX 2,053.10, while still holding above the SMA-200 at GBX 1,799.05. The Ichimoku Kijun at GBX 2,016.75 acts as immediate overhead resistance. Momentum indicators further emphasize the lack of bullish signals: MACD and ADX are both on sell readings, the RSI stands at 27.08, and CCI at –121.75, all confirming oversold status. Stoch RSI echoes this oversold condition, while BBP points to persistent seller dominance. The Awesome Oscillator remains negative. Notably, a small bullish gap formed between the previous close (GBX 1,843.00) and today's open (GBX 1,860.15), but the price lingers near the session lows, reflecting only moderate intraday volatility and a continued absence of upward momentum.

Downside risk rises as sideways range dominates short-term outlook

In the short term, GSK is likely to trade sideways within the GBX 1,849.00 to GBX 1,875.00 volatility band relative to current levels. The probability of a meaningful price increase remains low (under 20%), with only one bullish signal among major weekly indicators, so a decline is more probable. A breakout above GBX 2,016.75 would be required to trigger upside targets, though this scenario would need a significant change in momentum. If the price fails to hold above the SMA-200 at GBX 1,799.05, further downside is likely, with the risk of accelerating selling pressure.

Anton Kharitonov, analyst at Traders Union, notes the ongoing buyback and new commercial partnership, but remains cautious. He highlights technical weakness, with the price stuck below key moving averages and most momentum indicators signaling seller control. Kharitonov sees the lack of bullish confirmation outweighing the buyback's positive impact for now. "Without a strong push above GBX 2,016.75, I see little reason to expect meaningful upside in the near term."

Earlier, analysts noted that GSK was experiencing persistent technical weakness and downside risks in the short term. The ongoing oversold momentum, combined with slow progress in clearing overhead resistance, keeps the focus on the risk of further downside if the price fails to maintain support above the SMA-200 in the coming sessions.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.